Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    Open Studies | "Plasmacytoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Plasmacytoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Condition: Plasmacytoma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Other: No further treatment
2 Recruiting Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
Condition: Solitary Osseous Plasmacytoma
Interventions: Drug: ixazomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: zoledronic acid
3 Recruiting CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
Condition: Extramedullary Plasmacytoma
Interventions: Drug: CDD;   Drug: CDD Plus Bortezomib
4 Recruiting Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Conditions: Plasmacytoma;   POEMS Syndrome
Interventions: Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Questionnaire Administration
5 Recruiting Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Plasma Cell Myeloma;   Plasmacytoma
Interventions: Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
6 Recruiting Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
7 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
8 Recruiting Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
9 Recruiting Registry of Older Patients With Cancer
Conditions: Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
10 Recruiting 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Device: 3'-deoxy-3'-[18F]fluorothymidine
11 Recruiting Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Daratumumab
12 Recruiting Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Conditions: Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
13 Recruiting Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders;   Multiple Myeloma;   Plasma Cell Neoplasm;   Plasma Cell Dyscrasia;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
14 Recruiting Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
Condition: Carcinoma
Intervention:
15 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
16 Not yet recruiting A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: uman recombinant Interleukin-2 (rhIL-2);   Biological: PNK-007

Study has passed its completion date and status has not been verified in more than two years.